Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Oct;51(5):1593-1595.
doi: 10.1007/s15010-023-02027-6. Epub 2023 Apr 1.

Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept

Dorra Guermazi  1 , Panos Arvanitis  1 , Dimitrios Farmakiotis  2
Affiliations
Comment

Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept

Dorra Guermazi et al. Infection. 2023 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

DF has received research support from Viracor, Astellas and Merck, and consultant fee from Viracor. All other authors have nothing to disclose.

Comment on

References

    1. Johnson MG, Strizki JM, Brown ML, Wan H, Shamsuddin HH, Ramgopal M, et al. Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial. Infection. 2023 doi: 10.1007/s15010-022-01959-9. - DOI - PMC - PubMed
    1. Radcliffe C, Palacios CF, Azar MM, Cohen E, Malinis M. Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge. Am J Transplant. 2022;22:2458–2463. doi: 10.1111/ajt.17098. - DOI - PMC - PubMed
    1. Gleeson S, Martin P, Thomson T, et al. Kidney transplant recipients and omicron: outcomes, effect of vaccines and the efficacy and safety of novel treatments. medRxiv. 2022 doi: 10.1101/2022.05.03.22274524. - DOI
    1. Lerner AH, Arvanitis P, Vieira K, Klein EJ, Farmakiotis D. mRNA vaccination decreases COVID-19-associated morbidity and mortality among organ transplant recipients: a contemporary cohort study. Open Forum Infect Dis. 2022;9:ofac503. doi: 10.1093/ofid/ofac503. - DOI - PMC - PubMed
    1. Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401:281–293. doi: 10.1016/S0140-6736(22)02597-1. - DOI - PMC - PubMed